Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
196.09B
Market cap196.09B
Price-Earnings ratio
25.59
Price-Earnings ratio25.59
Dividend yield
2.66%
Dividend yield2.66%
Average volume
2.44M
Average volume2.44M
High today
$368.73
High today$368.73
Low today
$361.73
Low today$361.73
Open price
$367.82
Open price$367.82
Volume
661.60K
Volume661.60K
52 Week high
$391.29
52 Week high$391.29
52 Week low
$269.77
52 Week low$269.77

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $363.34. The company's market cap stands at 196.09B, with a P/E ratio of 25.59 and a dividend yield of 2.66%.

During the trading session on 2026-07-09, Amgen(AMGN) shares reached a daily high of $368.73 and a low of $361.73. At a current price of $363.34, the stock is +0.4% higher than the low and still -1.5% under the high.

Trading activity shows a volume of 661.6K, compared to an average daily volume of 2.44M.

The stock's 52-week range extends from a low of $269.77 to a high of $391.29.

The stock's 52-week range extends from a low of $269.77 to a high of $391.29.

AMGN News

TipRanks 1d
Amgen price target lowered to $333 from $340 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Amgen (AMGN) to $333 from $340 and keeps an Equal Weight rating on the shares. Biotech could benefit from broa...

Simply Wall St 4d
Amgen Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap

Amgen (AMGN) is back in focus after a federal judge blocked Colorado’s proposed 70% price cap on Enbrel, which removed an immediate regulatory threat to one of...

Amgen Could Be 45% Below Fair Value As Court Blocks Enbrel Price Cap
The Motley Fool 5d
Alphabet Officially Joins the Dow. These 3 Dow Dividend Stocks Are Better Buys for July.

The Dow Jones Industrial Average looks different this month. Before trading opened on June 29, Alphabet (GOOGL 0.23%) (GOOG 0.48%) took Verizon Communications'...

Alphabet Officially Joins the Dow. These 3 Dow Dividend Stocks Are Better Buys for July.

Analyst ratings

49%

of 35 ratings
Buy
40%
Hold
48.6%
Sell
11.4%

More AMGN News

Nasdaq 6d
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug

Roche RHHBY reported positive results from the late-stage Krascendo 1 study evaluating experimental candidate, divarasib, in patients with previously treated KR...

Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.